El-Khazragy N.Elshimy A.A.Hassan S.S.Matbouly S.Safwat G.Zannoun M.Riad R.A.Department of Clinical Pathology and HematologyFaculty of MedicineAin Shams Medical Research Institute (MASRI)Ain Shams UniversityCairoEgypt; Former Department of Biomedical ResearchArmed Forces College of Medicine (AFCM)CairoEgypt; Department of Medical Microbiology and ImmunologyFaculty of MedicineCairo UniversityNew Giza UniversityCairoEgypt; Department of Clinical PathologyNational Cancer InstituteCairo UniversityCairoEgypt; Department of PediatricsFaculty of MedicineAin Shams UniversityCairoEgypt; Department of Cancer BiologyFaculty of BiotechnologyOctober University for Modern Sciences and Art (MSA) UniversityCairoEgypt; Department of PediatricsFaculty of MedicineAl Azhar UniversityCairoEgypt; Department of Biotechnology and Molecular BiologyGlobal Research LabCairoEgypt2020-01-092020-01-0920197302312https://doi.org/10.1002/jcb.28017PubMedIDhttps://t.ly/2ddvRScopusMSA Google ScholarBackground: Acute lymphoblastic leukemia (ALL) is the most well-known sort of leukemia in children. In spite of favorable survival rates, some patients relapse and achieve a poor outcome. Methods: We analyzed miR-125b and Bcl-2 expressions in pediatric patients with ALL and evaluated their clinical utility as molecular markers for the prediction of disease outcomes. Results: Downregulation of miR-125b and increased Bcl-2 expression levels in pediatric patients with ALL were associated with poor prognosis at diagnosis. At day 28 of induction, miR-125b was significantly increased, whereas Bcl-2 was downregulated. Loss of miR-125b during diagnosis and its elevation after therapy are strongly correlated with short leukemia-free survival and worse survival. Moreover, the combination of miR-125b with Bcl-2 markers can clearly enhance the prediction of the disease outcome. Finally, a univariate analysis highlighted the independent prognostic value of miR-125 in a pediatric patient with ALL. Conclusions: miR-125b and Bcl-2 together are potent predictors for the prognosis and, therefore, can be used as therapeutic targets in childhood ALL. � 2018 Wiley Periodicals, Inc.EnglishOctober University for Modern Sciences and Artsجامعة أكتوبر للعلوم الحديثة والآدابUniversity of Modern Sciences and ArtsMSA UniversityBcl-2childhood acute lymphoblastic leukemia (ALL)miR-125bprognostic factorsantileukemic agentmicroRNA 125bprotein bcl 2acute lymphoblastic leukemiaArticlecancer chemotherapycancer prognosiscancer specific survivalchildchildhood leukemiaclinical outcomecontrolled studydown regulationfemalegene expressionhumanmajor clinical studymalepredictive valuepriority journaltreatment responseArticlehttps://doi.org/10.1002/jcb.28017PubMedID